[{"Assets_0_FY_USD":655294000.0,"CommonStockSharesOutstanding_0_FY_shares":296209426.0,"EarningsPerShareBasic_1_FY_USD":0.13,"EarningsPerShareBasic_4_FY_USD":0.52,"EarningsPerShareDiluted_1_FY_USD":0.12,"EarningsPerShareDiluted_4_FY_USD":0.49,"NetCashProvidedByUsedInOperatingActivities_4_FY_USD":165611000.0,"NetIncomeLoss_4_FY_USD":154227000.0,"NetIncomeLoss_1_FY_USD":38489000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_4_FY_shares":312003000.0,"WeightedAverageNumberOfSharesOutstandingBasic_4_FY_shares":293588000.0,"Ticker":"EXEL","CIK":"939767","name":"EXELIXIS, INC.","OfficialName":"Exelixis Inc. Common Stock","form":"10-K","period":"20171231","fy":"2017.0","fp":"FY","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"7287350058.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20180226"}]